Co-Diagnostics
CODX
30 hedge funds and large institutions have $940K invested in Co-Diagnostics in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 8 closing their positions.
660% more call options, than puts
Call options by funds: $38K | Put options by funds: $5K
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0.18% less ownership
Funds ownership: 0.49% → 0.3% (-0.18%)
9% less funds holding
Funds holding: 33 → 30 (-3)
38% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 8
51% less capital invested
Capital invested by funds: $1.93M → $940K (-$993K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73.7K |
| 2 |
Jane Street
New York
|
+$64.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$46.9K |
| 4 |
SFWA
Summit Financial Wealth Advisors
Lafayette,
Louisiana
|
+$14.5K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$11.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HF
HRT Financial
New York
|
-$51K |
| 2 |
Renaissance Technologies
New York
|
-$49.8K |
| 3 |
VF
Virtu Financial
New York
|
-$44K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$31.5K |
| 5 |
Group One Trading
Chicago,
Illinois
|
-$19.7K |
CODX Hedge Fund Activity: Q4 2025 in Review
30 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Co-Diagnostics (CODX) for Q4 2025, worth a combined $940K — down 51% from $1.93M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of CODX and 5 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Vanguard Group, adding an estimated $73.7K. The largest seller was HRT Financial, exiting entirely with an estimated $51K sold.
- 30 institutional investors held Co-Diagnostics (CODX) as of Q4 2025, down from 33 in Q3 2025.
- Funds reported $940K of Co-Diagnostics stock for Q4 2025, down 51% quarter-over-quarter.
- 5 funds opened new Co-Diagnostics positions in Q4 2025 and 8 closed out, a net change of -3 holders.
- The largest Co-Diagnostics buyer in Q4 2025 was Vanguard Group, an estimated $73.7K added.
- The largest Co-Diagnostics seller in Q4 2025 was HRT Financial, an estimated $51K sold.
Based on aggregated 13F filings for Q4 2025.